Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotech company with a market capitalization of $92 million, recently acquired 5,000 shares of the company's common stock. According to InvestingPro analysis, the stock is currently trading below its Fair Value, suggesting potential upside opportunity. The shares were purchased on December 5th at a weighted average price of $2.34 per share, with the total transaction amounting to $11,700. This purchase increases Magovcevic-Liebisch's direct ownership to 212,687 shares. The shares were acquired in multiple transactions, with prices ranging from $2.33 to $2.34. InvestingPro data shows the stock is currently in oversold territory, with the price down over 33% in the past six months. The company maintains a strong liquidity position with a current ratio of 3.72, though investors should note that 10+ additional insights are available with an InvestingPro subscription.
In other recent news, Vigil Neuroscience received an Outperform rating from William Blair, with the firm setting a fair value of $18.67 per share. The company is advancing in Alzheimer's treatment, focusing on developing therapeutics targeting TREM2. This approach could potentially address the needs of a broad patient population suffering from CNS-related degenerative diseases.
Vigil Neuroscience also reported promising results from its Phase I study of VG-3927, an Alzheimer's disease treatment. Following these developments, Guggenheim reiterated its Buy rating on the company, while JMP Securities maintained its Market Outperform rating and a $23.00 stock price target.
The U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on Vigil Neuroscience's Phase 1 clinical trial of VG-3927, allowing the company to potentially increase the drug's exposure limit in the ongoing study. The company plans to report the complete Phase I data, including results from the Alzheimer's disease patient cohort, in the first quarter of 2025.
On another note, Guggenheim reiterated its Buy rating on Vigil Neuroscience following the announcement of Phase II trial results by Alector (NASDAQ:ALEC) for its Alzheimer's disease treatment. The company remains optimistic about its own Alzheimer's disease treatment, VG-3927, which is a small molecule TREM2 agonist.
Lastly, JMP Securities maintained its Market Outperform rating and a $23.00 stock price target for Vigil Neuroscience, anticipating Phase 2 results for Alector's AL002, which could serve as a validation for Vigil Neuroscience's small molecule TREM2 agonist, VG-3927.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.